AJANTPHARM.BOAJANTPHARM.BOBSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +3.71% | +11.04% | +13.78% | +14.08% | +19.95% |
| Gross Profit Growth | +9.54% | +69.94% | +17.07% | -26.81% | -19.56% |
| EBITDA Growth | +7.21% | -8.12% | +5.85% | +17.09% | +15.93% |
| Operating Income Growth | -0.88% | +122.97% | +35.80% | -48.25% | +18.91% |
| Net Income Growth | +10.88% | +11.12% | +3.89% | +20.19% | +17.56% |
| EPS Growth | +11.51% | +12.05% | +4.61% | +20.61% | +17.80% |
| EPS Diluted Growth | +11.52% | +12.12% | +4.61% | +20.63% | +17.86% |
| Weighted Average Shares Growth | -0.56% | -0.83% | -0.68% | -0.33% | -0.21% |
| Weighted Average Shares Diluted Growth | -0.57% | -0.89% | -0.68% | -0.36% | -0.27% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -5.14% | +0.00% | +39.84% | +0.00% |
| Inventory Growth | +0.00% | +9.11% | +0.00% | -3.96% | +0.00% |
| Asset Growth | +0.00% | +8.12% | +0.00% | +18.41% | +0.00% |
| Book Value per Share Growth | +6.20% | +7.14% | +6.98% | +17.74% | +0.00% |
| Debt Growth | +0.00% | +34.41% | +0.00% | +649.89% | +0.00% |
| R&D Expense Growth | +1.92% | +26.00% | +9.80% | +10.53% | +18.87% |
| SG&A Expenses Growth | +21.04% | +22.78% | +37.48% | -2.44% | +25.47% |